-
Something wrong with this record ?
Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia
K. Cermakova, C. Weydert, F. Christ, J. De Rijck, Z. Debyser,
Trends in pharmacological sciences.
2016 ;
37 (8) :
660-671.
[pub] 20160609
Language English Country Great Britain
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/bmc18017209
- MeSH
- Adaptor Proteins, Signal Transducing genetics metabolism MeSH
- Molecular Targeted Therapy MeSH
- Histone-Lysine N-Methyltransferase genetics metabolism MeSH
- HIV Infections drug therapy genetics metabolism MeSH
- Precision Medicine methods MeSH
- Protein Interaction Domains and Motifs MeSH
- Small Molecule Libraries pharmacology MeSH
- Contraindications MeSH
- Leukemia drug therapy genetics metabolism MeSH
- Humans MeSH
- Models, Molecular MeSH
- Myeloid-Lymphoid Leukemia Protein genetics metabolism MeSH
- Transcription Factors genetics metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Protein-protein interactions are involved in most if not all pathogenic and pathophysiological processes and represent attractive therapeutic targets. Extensive biological and clinical research efforts have led to the identification and validation of several cellular hubs that are crucially involved in disease pathogenesis. An interesting example of such a hub is the lens epithelium-derived growth factor (LEDGF/p75), a protein that tethers multiple unrelated proteins and protein complexes to the chromatin. Its chromatin-tethering ability is linked to at least two unrelated diseases-HIV infection and MLL-rearranged acute leukemia. In this review we discuss recent progress in our understanding of the interaction of LEDGF/p75 with its binding partners and focus on the first steps towards therapies targeting protein-protein interactions of LEDGF/p75.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017209
- 003
- CZ-PrNML
- 005
- 20180521123922.0
- 007
- ta
- 008
- 180515s2016 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.tips.2016.05.005 $2 doi
- 035 __
- $a (PubMed)27290878
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Cermakova, Katerina $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium; Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (ASCR), v.v.i, Laboratory of Structural Biology, Prague, Czech Republic.
- 245 10
- $a Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia / $c K. Cermakova, C. Weydert, F. Christ, J. De Rijck, Z. Debyser,
- 520 9_
- $a Protein-protein interactions are involved in most if not all pathogenic and pathophysiological processes and represent attractive therapeutic targets. Extensive biological and clinical research efforts have led to the identification and validation of several cellular hubs that are crucially involved in disease pathogenesis. An interesting example of such a hub is the lens epithelium-derived growth factor (LEDGF/p75), a protein that tethers multiple unrelated proteins and protein complexes to the chromatin. Its chromatin-tethering ability is linked to at least two unrelated diseases-HIV infection and MLL-rearranged acute leukemia. In this review we discuss recent progress in our understanding of the interaction of LEDGF/p75 with its binding partners and focus on the first steps towards therapies targeting protein-protein interactions of LEDGF/p75.
- 650 _2
- $a adaptorové proteiny signální transdukční $x genetika $x metabolismus $7 D048868
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kontraindikace $7 D000075202
- 650 _2
- $a HIV infekce $x farmakoterapie $x genetika $x metabolismus $7 D015658
- 650 _2
- $a histonlysin-N-methyltransferasa $x genetika $x metabolismus $7 D011495
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie $x farmakoterapie $x genetika $x metabolismus $7 D007938
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a protoonkogenní protein MLL $x genetika $x metabolismus $7 D051788
- 650 _2
- $a individualizovaná medicína $x metody $7 D057285
- 650 _2
- $a interakční proteinové domény a motivy $7 D054730
- 650 _2
- $a knihovny malých molekul $x farmakologie $7 D054852
- 650 _2
- $a transkripční faktory $x genetika $x metabolismus $7 D014157
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Weydert, Caroline $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
- 700 1_
- $a Christ, Frauke $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
- 700 1_
- $a De Rijck, Jan $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
- 700 1_
- $a Debyser, Zeger $u KU Leuven, Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium. Electronic address: Zeger.Debyser@kuleuven.be.
- 773 0_
- $w MED00010701 $t Trends in pharmacological sciences $x 1873-3735 $g Roč. 37, č. 8 (2016), s. 660-671
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27290878 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180521124104 $b ABA008
- 999 __
- $a ok $b bmc $g 1300833 $s 1014049
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 37 $c 8 $d 660-671 $e 20160609 $i 1873-3735 $m Trends in pharmacological sciences $n Trends Pharmacol Sci $x MED00010701
- LZP __
- $a Pubmed-20180515
